Value-based pricing in pharmaceuticals

Guide to annual financial statements: IFRS 9 ...

Notes Basis of preparation 16 1. Reporting entity 16 2. Basis of accounting 16 3. Functional and presentation currency 16 4. Use of judgements and estimates 16

  Guide, Ifrs

Customer-led transformation in retail banking - assets.kpmg

kpmg.com July, 2018. Retail banks can create superior customer experiences by balancing . the priorities of the 5Cs. Customer-led . transformation in retail banking

  Bank

AASB 16 Leases - assets.kpmg

AASB 16 Leases KPMG.com.au A fundamental overhaul of lessee accounting effective 2019

  Accounting, Fundamentals, Overhaul, Aasb, Lessee, Kpmg, Aasb 16, Fundamental overhaul, Lessee accounting

UAE 2018 Food & Beverage report - assets.kpmg

This is the fourth edition of our annual series which examines the current state of the United Arab Emirate’s (UAE) Food & Beverage (F&B) industry.

ESG, strategy, and the long view - assets.kpmg

From our perspective, many of these issues fall under the broad rubric of environmental, social, and governance (ESG), from climate change impacts and worker safety to …

  Safety

The Power of Procurement - assets.kpmg

And as the world continues to wade through its fi nancial morass, the Procurement function will also fi nd itself under increasing pressure in areas currently considered

IFRS compared to US GAAP - assets.kpmg

A changing focus. Both the FASB and the IASB believe that the era of sweeping accounting change has come to an end, for now, and both are committed to helping companies

Modular Construction Report - assets.kpmg

Foreword Many construction projects have a reputation for being completed behind schedule and over budget. While these companies have tried to improve project time, cost and

  Construction

Example Public Company Limited - assets.kpmg

f | Example Public Company Limited – illustrative disclosures Contents From implementation to disclosure b How to use this guide c Further KPMG Guidance d What’s new?

  Guidance

Cloud Economics: Making the Business Case for Cloud

2 Making the Business Case for Cloud Cloud computing can enable innovation, dramatically reduce capital and operating costs, increase agility, and reduce time to market for new products and services.

  Economic

The next phase: Opportunities in China's pharmaceuticals ...

22 3.4 Pricing 22 3.5 Reimbursement 23 4. Summary 25 M&A highlights 28 1. Domestic M&A surges as pharmaceutical players lead a new wave of consolidation 31 2. Inbound M&A activity making a gradual recovery 34 2.1 Inbound acquisitions

  Pharmaceutical, Pricing

ASEAN Pharma Report: Opportunities & Threats 2020 and …

Pharmaceutical Association of Malaysia (Phama) has many concerns with the drug pricing strategy, notably that patient access to the newest medicines may be put at risk as international manufacturers may possibly withdraw their products from the market due to unfavourable business conditionsix. Both foreign and domestic pharmaceutical

  Pharmaceutical, Pricing

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for

  Pharmaceutical, Pricing, Pharmaceutical pricing

Update of Drug Pricing System in Japan - Pmda

Pricing Rule for New Pharmaceuticals SAKIGAKE Designation System: promoting R&D in Japan aiming at early practical application for innovative pharmaceutical products, medical devices, and regenerative medicines. –“SAKIGAKE” means “taking the lead [initiative],” 13

  Pharmaceutical, Pricing

Operational principles for good pharmaceutical procurement

Pharmaceutical procurement is a complex process which involves many steps, agencies, ministries and manufacturers. Existing government policies, rules and regulations for procurement as well as institutional structures are frequently ... Unbiased market information onproduct availability, comparative pricing,

  Pharmaceutical, Pricing

PHARMACEUTICAL REIMBURSEMENT AND PRICING IN …

6 │ PHARMACEUTICAL REIMBURSEMENT AND PRICING IN GERMANY © OECD 2018 “added therapeutic benefit” of new medicines in order to negotiate the price according to

  Code, Pharmaceutical, Reimbursement, Pricing, Pharmaceutical reimbursement and pricing in

Pharmaceutical pricing and reimbursement policies in ...

Pharmaceuticals pricing and reimbursement policies in Europe WHO TBS – October 2016 Direct price control • Example 1: External Reference Pricing • The practice of using the price(s) of a pharmaceutical product in one or several countries in order to derive a benchmark (or reference price) for the purposes of setting

  Pharmaceutical, Policies, Reimbursement, Europe, Pricing, Pricing and reimbursement policies in europe, Pharmaceutical pricing and reimbursement policies in

Pharmaceutical regulation in 15 European countries

Pharmaceutical regulation in 15 European countries Review Vol. 18 No. 5 2016 Health Systems in Transition Dimitra Panteli • Francis Arickx • Irina Cleemput Guillaume Dedet • Helene Eckhardt • Emer Fogarty Sophie Gerkens • Cornelia Henschke • Jennifer Hislop Claudio Jommi • Daphne Kaitelidou • Pawel Kawalec Ilmo Keskimäki • Madelon Kroneman • Julio Lopez Bastida

  Pharmaceutical, European, Regulations, Countries, Pharmaceutical regulation in 15 european countries

THE PANDEMIC AND THE SUPPLY CHAIN Addressing Gaps in ...

pharmaceutical ingredients6 and finished pharmaceutical products. China is a major source of active pharmaceutical ingredients7 for antibiotics, antihypertensives and antivirals. Due to the pandemic8, many factories in China had to close temporarily8, leading to a halt in production5 of active pharmaceutical ingredientsand finished products.

  Pharmaceutical